...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
【24h】

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease

机译：Tenuigenin和β-asaron的联合应用提高了美金刚治疗中重度阿尔茨海默氏病的疗效

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Alzheimer’s disease (AD) is a slowly progressive neurodegenerative disease which cannot be cured at present. The aim of this study was to assess whether the combined application of β-asarone and tenuigenin could improve the efficacy of memantine in treating moderate-to-severe AD. Patients and methods: One hundred and fifty-two patients with moderate-to-severe AD were recruited and assigned to two groups. Patients in the experiment group received β-asarone 10 mg/d, tenuigenin 10?mg/d, and memantine 5–20 mg/d. Patients in the control group only received memantine 5–20 mg/d. The Mini Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR), and Activities of Daily Living (ADL) were used to assess the therapeutic effects. The drug-related adverse events were used to assess the safety and acceptability. Treatment was continued for 12?weeks. Results: After 12 weeks of treatment, the average MMSE scores, ADL scores, and CDR scores in the two groups were significantly improved. But, compared to the control group, the experimental group had a significantly higher average MMSE score ( p <0.00001), lower average ADL score ( p =0.00002), and lower average CDR score ( p =0.030). Meanwhile, the rates of adverse events were similar between the two groups. Subgroup analysis indicated that the most likely candidates to benefit from this novel method might be the 60–74-years-old male patients with moderate AD. Conclusion: These results demonstrated that the combined application of β-asarone and tenuigenin could improve the efficacy of memantine in treating moderate-to-severe AD. The clinical applicability of this novel method showed greater promise and should be further explored.
机译：背景：阿尔茨海默氏病（AD）是一种缓慢进行性神经退行性疾病，目前尚无法治愈。这项研究的目的是评估β-细辛和牛藤黄素联合应用是否可以改善美金刚治疗中重度AD的疗效。患者和方法：招募了152例中度至重度AD患者，并分为两组。实验组患者接受β-细辛醚10 mg / d，肌腱蛋白10？mg / d和美金刚5-20 mg / d。对照组患者仅接受美金刚5-20 mg / d。迷你精神状态检查（MMSE），临床痴呆评定量表（CDR）和日常生活活动（ADL）用于评估治疗效果。药物相关的不良事件用于评估安全性和可接受性。治疗持续了12周。结果：治疗12周后，两组的MMSE平均得分，ADL得分和CDR得分均得到明显改善。但是，与对照组相比，实验组的平均MMSE评分（p <0.00001），平均ADL评分（p = 0.00002）和CDR评分（p = 0.030）均明显较低。同时，两组的不良事件发生率相似。亚组分析表明，最可能从这种新方法中受益的候选人可能是60-74岁的中度AD男性患者。结论：这些结果表明，β-细辛和牛藤黄素联合应用可提高美金刚治疗中重度AD的疗效。这种新方法的临床适用性显示出更大的希望，应进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号